ACADIA Pharmaceuticals (NASDAQ:ACAD) Insider Sells $29,024.28 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 1,332 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $21.79, for a total transaction of $29,024.28. Following the completion of the transaction, the insider owned 29,129 shares of the company’s stock, valued at $634,720.91. This trade represents a 4.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

James Kihara also recently made the following trade(s):

• On Tuesday, April 7th, James Kihara sold 1,030 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $22.20, for a total transaction of $22,866.00.

ACADIA Pharmaceuticals Trading Up 5.1%

Shares of NASDAQ ACAD opened at $22.58 on Friday. ACADIA Pharmaceuticals Inc. has a 12 month low of $14.68 and a 12 month high of $28.35. The firm has a market capitalization of $3.87 billion, a PE ratio of 10.26, a price-to-earnings-growth ratio of 22.40 and a beta of 0.86. The firm has a fifty day simple moving average of $22.06 and a two-hundred day simple moving average of $23.90.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The business had revenue of $268.10 million during the quarter, compared to analysts’ expectations of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 10.23% and a net margin of 34.30%.The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.11 earnings per share. On average, sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.45 earnings per share for the current year.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ACAD. Dimensional Fund Advisors LP grew its holdings in ACADIA Pharmaceuticals by 8.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company’s stock valued at $70,222,000 after buying an additional 234,186 shares in the last quarter. Swiss National Bank grew its holdings in ACADIA Pharmaceuticals by 0.6% during the 1st quarter. Swiss National Bank now owns 234,404 shares of the biopharmaceutical company’s stock valued at $5,218,000 after buying an additional 1,500 shares in the last quarter. Bessemer Group Inc. grew its holdings in ACADIA Pharmaceuticals by 21,126.8% during the 1st quarter. Bessemer Group Inc. now owns 150,498 shares of the biopharmaceutical company’s stock valued at $3,350,000 after buying an additional 149,789 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in ACADIA Pharmaceuticals by 44.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 954,855 shares of the biopharmaceutical company’s stock valued at $21,312,000 after buying an additional 296,042 shares in the last quarter. Finally, Illinois Municipal Retirement Fund grew its holdings in ACADIA Pharmaceuticals by 12.7% during the 1st quarter. Illinois Municipal Retirement Fund now owns 71,183 shares of the biopharmaceutical company’s stock valued at $1,585,000 after buying an additional 7,996 shares in the last quarter. Institutional investors own 96.71% of the company’s stock.

Key Stories Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Management highlighted strong early uptake of DAYBUE (DAYBUE STIX now broadly available) and said DAYBUE generated roughly $101M in Q1—supporting near-term revenue momentum and commercial execution. Acadia Q1 release
• Positive Sentiment: Company reaffirmed its full?year 2026 financial guidance (revenue range reiterated), which reduced downside uncertainty despite the quarter’s miss on street EPS and revenue. Guidance reaffirmation
• Neutral Sentiment: Full earnings presentation and the call transcript are available for investors wanting detail on commercial uptake, margin dynamics and pipeline updates—useful for modeling forward sales and margin trajectory. Earnings slide deck Earnings call transcript
• Negative Sentiment: Q1 EPS missed estimates: $0.02 vs. consensus $0.04, and revenue came in at $268.1M vs. ~$280M consensus. The EPS decline vs. prior year weakens near-term profitability optics and drove some analyst and media scrutiny. Zacks earnings summary
• Negative Sentiment: Insider selling disclosed (small volume): an officer sold ~1.3K shares recently—minor but noted by some investors. Insider trade filing

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Weiss Ratings downgraded shares of ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Wolfe Research assumed coverage on shares of ACADIA Pharmaceuticals in a research note on Monday, February 23rd. They set an “outperform” rating and a $33.00 target price on the stock. TD Cowen upped their target price on shares of ACADIA Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Mizuho upgraded shares of ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their target price for the company from $29.00 to $35.00 in a research note on Monday, February 23rd. Finally, Oppenheimer reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $31.21.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.